No Data
No Data
Immutep Secures US FDA Guidance for Phase Three Lung Cancer Trial
Immutep (ASX:IMM) secured guidance from the US Food and Drug Administration related to the design of its upcoming phase three lung cancer trial, according to a Monday filing with the Australian
Guess Which ASX Healthcare Stock Is Surging on Big FDA News
ASX healthcare stock Immutep Ltd (ASX: IMM) is surging after the company released a market-sensitive announcement before the open on Monday.
Immutep Receives Positive FDA Feedback
Immutep (ASX:IMM; NASDAQ:IMMP), a leading biotechnology firm specialising in LAG-3 immunotherapy, has achieved a significant milestone in its quest to redefine cancer treatment. Today, the company
Why 29Metals, Immutep, Insignia, and Perenti Shares Are Pushing Higher Today
The S&P/ASX 200 Index (ASX: XJO) is having a tough time on Monday. In afternoon trade, the benchmark index is down 0.9% to 7,902.4 points.
Jefferies Remains a Buy on Immutep Ltd (PRRUF)
Immutep Secures Regulatory Clearance for Phase 1 Antibody Study in Autoimmune Diseases; Shares Up 3%
Immutep (ASX:IMM) secured regulatory clearance from the ethics and competent authority in the Netherlands for its phase one study investigating the safety, pharmacokinetic, and pharmacodynamic
No Data